News & Updates
Filter by Specialty:
Temporary ET break for pregnancy safe in the short term for breast cancer survivors
Temporary interruption of adjuvant endocrine therapy (ET) to allow for pregnancy has demonstrated short-term safety, with no increase in risk of breast cancer events, including distant recurrence, in hormone receptor–positive breast cancer survivors who have completed 18–30 months of adjuvant ET.
Temporary ET break for pregnancy safe in the short term for breast cancer survivors
09 May 2023
Psilocybin shows promise in relieving depression in cancer patients
The 5-HT2A receptor agonist psilocybin, when taken under medical supervision, may offer a promising approach to treatment of major depressive disorder (MDD) in cancer patients, results of a small phase II study suggest.
Psilocybin shows promise in relieving depression in cancer patients
08 May 2023
Second primary melanoma tied to better survival than single primary lesion
Patients who present with second primary melanomas have better survival and thinner lesions than those presenting with single primary melanomas, reveals a study.
Second primary melanoma tied to better survival than single primary lesion
06 May 2023
Immune-related AEs predict survival in cancer patients on ICI
Developing cutaneous immune-related adverse events (cirAEs) among advanced cancer patients on immune checkpoint inhibitor (ICI) appears to be a sign of longer overall survival, particularly in those with melanoma, suggests a recent study.